Soft Tissue Sarcoma Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, and Growth Prospects | Philogen, Nanobiotix, Monopar, OncoTherapy Science, Foghorn

The Soft Tissue Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Soft Tissue Sarcoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Soft Tissue Sarcoma Market.

Some of the key takeaways from the Soft Tissue Sarcoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Soft Tissue Sarcoma treatment therapies with a considerable amount of success over the years. 
• Soft Tissue Sarcoma companies working in the treatment market are OncoTherapy Science, Inc., Foghorn Therapeutics Inc., C4 Therapeutics, Inc., Lyvgen Biopharma, Chipscreen Biosciences, Ltd., Monopar Therapeutics, Advenchen Laboratories, Philogen S.p.A., Advenchen Laboratories, Philogen, Nanobiotix, Monopar Therapeutics, Lytix Biopharma, Jazz Pharmaceuticals, and others, are developing therapies for the Soft Tissue Sarcoma treatment 

• Emerging Soft Tissue Sarcoma therapies in the different phases of clinical trials are- OTSA101-DTPA111In, FHD-609, CFT8634, LVGN6051 + Anlotinib, Chiauranib, MNPR 201, AL3818, Fibronum + Doxorubicin, AL3818, L19 TNF, NBTXR3, GPX-150, LTX-315, Lurbinectedin, and others are expected to have a significant impact on the Soft Tissue Sarcoma market in the coming years.   
• In October 2022, LIXTE Biotechnology Holdings, Inc. disclosed that the Spanish Agency for Medicines and Health Products (AEMPS) has granted approval for a Phase 1b/randomized Phase 2 trial involving LB-100, the company’s primary clinical compound. The study aims to evaluate LB-100 in combination with doxorubicin compared to using doxorubicin alone, which is the established global standard for initial treatment of advanced soft tissue sarcomas (ASTS).
• In September 2022, Immutep Limited has happily confirmed the signing of a Material Transfer Agreement (“Agreement”) with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland. This agreement facilitates an investigator-initiated open-label Phase II clinical trial aiming to assess Immutep’s primary product candidate, efti, in combination with pembrolizumab and radiotherapy administered before surgery, in a cohort of up to 40 patients diagnosed with specific types of soft tissue sarcoma (STS).
• In September 2022, TRACON Pharmaceuticals, Inc. disclosed that the U.S. Food and Drug Administration (FDA) has provided fast-track designation for advancing the development of envafolimab (KN035) intended for patients diagnosed with locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS). This designation applies specifically to individuals who have experienced progression following one or two prior lines of chemotherapy.
• In September 2022, Avacta Group plc revealed that the US Food and Drug Administration (FDA) awarded Orphan Drug Designation (ODD) to AVA6000, the company’s primary pre|CISION drug candidate developed for treating soft tissue sarcoma. AVA6000 is a modified version of the standard chemotherapy drug doxorubicin, employing pre|CISION technology to enhance its activation mainly within the tumor, aiming to minimize healthy tissue exposure. This modification seeks to improve the drug’s safety, tolerance, and effectiveness.
• In May 2022, Immix Biopharma, Inc., released promising interim findings indicating that following a single treatment cycle, the leading candidate IMX-110 demonstrated a 75% survival rate, compared to a 0% survival rate observed with Trabectedin (marketed as YONDELIS ® by Janssen, a Johnson & Johnson Company, an FDA-approved drug) in a mouse study modeling Soft Tissue Sarcoma (STS). The study involved a comparison between IMX-110 and established drugs utilized for STS treatment. Trabectedin was administered per the protocol outlined by Meco et al., 2003 (trabectedin monotherapy treatment arm), while IMX-110 was delivered at a dosage of 2.0 mg/kg.
• In April 2022, Telix Pharmaceuticals Limited disclosed its licensing deal with Eli Lilly and Company (“Lilly”), securing exclusive global rights to develop and market radiolabelled versions of Lilly’s olaratumab antibody for diagnosing and treating human cancers. Telix’s primary focus in its developmental efforts will be directed toward a less common form of cancer identified as soft tissue sarcoma (STS).

Soft Tissue Sarcoma Overview

A uncommon kind of cancer called soft tissue sarcoma starts in the tissues that encircle, support, and link other bodily parts. This comprises your blood vessels, muscles, adipose tissue, nerves, tendons, and joint lining. Soft tissue sarcoma has more than 50 subtypes.Certain varieties tend to primarily impact adults, while others are more likely to affect youngsters.

Get a Free Sample PDF Report to know more about Soft Tissue Sarcoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight

Emerging Soft Tissue Sarcoma Drugs Under Different Phases of Clinical Development Include:

• OTSA101-DTPA111In: OncoTherapy Science, Inc.
• FHD-609: Foghorn Therapeutics Inc.
• CFT8634: C4 Therapeutics, Inc.
• LVGN6051 + Anlotinib: Lyvgen Biopharma Holdings Limited
• Chiauranib: Chipscreen Biosciences, Ltd.
• MNPR 201: Monopar Therapeutics
• AL3818: Advenchen Laboratories, LLC
• Fibronum + Doxorubicin: Philogen S.p.A.
• AL3818: Advenchen Laboratories
• L19 TNF: Philogen
• NBTXR3: Nanobiotix
• GPX-150: Monopar Therapeutics
• LTX-315: Lytix Biopharma
• Lurbinectedin: Jazz Pharmaceuticals

Soft Tissue Sarcoma Route of Administration

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Soft Tissue Sarcoma Molecule Type

Soft Tissue Sarcoma Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Soft Tissue Sarcoma Pipeline Therapeutics Assessment

• Soft Tissue Sarcoma Assessment by Product Type
• Soft Tissue Sarcoma By Stage and Product Type
• Soft Tissue Sarcoma Assessment by Route of Administration
• Soft Tissue Sarcoma By Stage and Route of Administration
• Soft Tissue Sarcoma Assessment by Molecule Type
• Soft Tissue Sarcoma by Stage and Molecule Type

DelveInsight’s Soft Tissue Sarcoma Report covers around 130+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Soft Tissue Sarcoma product details are provided in the report. Download the Soft Tissue Sarcoma pipeline report to learn more about the emerging Soft Tissue Sarcoma therapies

Some of the key companies in the Soft Tissue Sarcoma Therapeutics Market include:

Key companies developing therapies for Soft Tissue Sarcoma are – Monopar Therapeutics, Jazz Pharmaceuticals, Moleculin Biotech, Inc., Advenchen Laboratories, LLC, Tracon Pharmaceuticals Inc., C4 Therapeutics, Inc., Eli Lilly and Company, Epizyme, Inc., Ipsen, GlaxoSmithKline, Salarius Pharmaceuticals, LLC, Mundipharma Research Limited, HiFiBiO Therapeutics, QBiotics Group Limited, Merck Sharp & Dohme LLC, Polaris Group, Philogen S.p.A., Agenus Inc, Apexigen America, Inc., Mirati Therapeutics Inc., and others.

Soft Tissue Sarcoma Pipeline Analysis:

The Soft Tissue Sarcoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Soft Tissue Sarcoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Soft Tissue Sarcoma Treatment.
• Soft Tissue Sarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Soft Tissue Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Soft Tissue Sarcoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Soft Tissue Sarcoma drugs and therapies

Soft Tissue Sarcoma Pipeline Market Drivers

• Increase in Cancer Cases, rising Involvement of Clinical Trials are some of the important factors that are fueling the Soft Tissue Sarcoma Market.

Soft Tissue Sarcoma Pipeline Market Barriers

• However, side-Effects of Soft Tissue Sarcoma Drugs, increasing Cost Of Treatments and other factors are creating obstacles in the Soft Tissue Sarcoma Market growth.

Scope of Soft Tissue Sarcoma Pipeline Drug Insight    

• Coverage: Global
• Key Soft Tissue Sarcoma Companies: OncoTherapy Science, Inc., Foghorn Therapeutics Inc., C4 Therapeutics, Inc., Lyvgen Biopharma, Chipscreen Biosciences, Ltd., Monopar Therapeutics, Advenchen Laboratories, Philogen S.p.A., Advenchen Laboratories, Philogen, Nanobiotix, Monopar Therapeutics, Lytix Biopharma, Jazz Pharmaceuticals, and others
• Key Soft Tissue Sarcoma Therapies: OTSA101-DTPA111In, FHD-609, CFT8634, LVGN6051 + Anlotinib, Chiauranib, MNPR 201, AL3818, Fibronum + Doxorubicin, AL3818, L19 TNF, NBTXR3, GPX-150, LTX-315, Lurbinectedin, and others
• Soft Tissue Sarcoma Therapeutic Assessment: Soft Tissue Sarcoma current marketed and Soft Tissue Sarcoma emerging therapies
• Soft Tissue Sarcoma Market Dynamics: Soft Tissue Sarcoma market drivers and Soft Tissue Sarcoma market barriers 

Request for Sample PDF Report for Soft Tissue Sarcoma Pipeline Assessment and clinical trials

Table of Contents

1. Soft Tissue Sarcoma Report Introduction

2. Soft Tissue Sarcoma Executive Summary

3. Soft Tissue Sarcoma Overview

4. Soft Tissue Sarcoma- Analytical Perspective In-depth Commercial Assessment

5. Soft Tissue Sarcoma Pipeline Therapeutics

6. Soft Tissue Sarcoma Late Stage Products (Phase II/III)

7. Soft Tissue Sarcoma Mid Stage Products (Phase II)

8. Soft Tissue Sarcoma Early Stage Products (Phase I)

9. Soft Tissue Sarcoma Preclinical Stage Products

10. Soft Tissue Sarcoma Therapeutics Assessment

11. Soft Tissue Sarcoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Soft Tissue Sarcoma Key Companies

14. Soft Tissue Sarcoma Key Products

15. Soft Tissue Sarcoma Unmet Needs

16 . Soft Tissue Sarcoma Market Drivers and Barriers

17. Soft Tissue Sarcoma Future Perspectives and Conclusion

18. Soft Tissue Sarcoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services